A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a clinical-stage biotechnology company pioneering the development of immunotherapies for patients with limited treatment options and poor outcomes suffering from cancer. Our proprietary Amphiphile (“AMP”) technology is designed to generate robust anti-tumor T cell responses by preferentially targeting lymph nodes. Recent advances have identified T cell responses as a key component of effective cancer immunotherapy and we believe our AMP technology can generate a robust T cell response that can potentially provide meaningful clinical benefit. We believe the therapeutic utility of currently approved and development stage cancer immunotherapies are limited in many cases due to their inability to sufficiently localize to lymph nodes and adequately engage with the critical immune cells responsible for stimulating adaptive immunity.
| Metric | TTM | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|
| Revenue | 0 | - | 28M | - |
| Net Income | -46M | -39M | -55M | -80M |
| EPS | $-3.11 | $-12.90 | $-19.30 | $-54.30 |
| Free Cash Flow | 0 | -38M | -53M | -23M |
| ROIC | -118.3% | -88.3% | -66.8% | -92.2% |
| Gross Margin | - | - | 98.4% | - |
| Debt/Equity | 2.55 | 0.00 | 0.00 | -0.01 |
| Dividends/Share | $0.00 | - | - | - |
| Operating Income | -42M | -40M | -39M | -55M |
| Operating Margin | 0.0% | - | -142.9% | - |
| ROE | -1201.7% | -62.0% | -67.0% | - |
| Shares Outstanding | 17M | 3M | 3M | 1M |
| Metric | 2020 | |||
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | N/A | 28M | N/A | 0 |
| Gross Margin | N/A | 98.4% | N/A | N/A |
| R&D | N/A | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A | N/A |
| EBIT | -55M | -39M | -40M | -42M |
| Op. Margin | N/A | -142.9% | N/A | 0.0% |
| Net Income | -80M | -55M | -39M | -46M |
| Net Margin | N/A | -198.4% | N/A | 0.0% |
| Non-Recurring | -58K | 0 | 9.2M | 9.2M |
| Returns on Capital | ||||
| ROIC | -92.2% | -66.8% | -88.3% | -118.3% |
| ROE | N/A | -67.0% | -62.0% | -1201.7% |
| ROA | -169.2% | -56.5% | -52.0% | -162.1% |
| Cash Flow | ||||
| Op. Cash Flow | -23M | -53M | -38M | -39M |
| Free Cash Flow | -23M | -53M | -38M | 0 |
| Owner Earnings | -28M | -65M | -39M | -40M |
| CapEx | 41K | 382K | 0 | 0 |
| Maint. CapEx | 98K | 91K | 178K | 178K |
| Growth CapEx | 0 | 291K | N/A | 0 |
| D&A | 98K | 91K | 178K | 178K |
| CapEx/OCF | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||
| Dividends Paid | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 4.7M | 12M | 885K | 885K |
| Debt Repayment | 0 | 0 | 0 | 0 |
| Balance Sheet | ||||
| Net Debt | -34M | -89M | -50M | -11M |
| Cash & Equiv. | N/A | N/A | N/A | 21M |
| Long-Term Debt | 635K | 235K | 168K | 168K |
| Debt/Equity | -0.01 | 0.00 | 0.00 | 2.55 |
| Interest Coverage | N/A | -43.4 | N/A | N/A |
| Equity | -90M | 82M | 44M | 3.8M |
| Total Assets | 47M | 97M | 53M | 28M |
| Total Liabilities | 138M | 15M | 9.0M | 24M |
| Intangibles | N/A | N/A | N/A | N/A |
| Retained Earnings | -161M | -215M | -254M | -254M |
| Working Capital | -65M | 80M | 45M | 45M |
| Current Assets | 42M | 91M | 51M | 51M |
| Current Liabilities | 107M | 11M | 6.4M | 6.4M |
| Per Share Data | ||||
| EPS | -54.30 | -19.30 | -12.90 | -3.11 |
| Owner EPS | -18.78 | -22.91 | -13.11 | -2.28 |
| Book Value | -61.31 | 28.83 | 14.55 | 0.22 |
| Cash Flow/Share | -15.51 | -18.62 | -12.76 | -2.61 |
| Dividends/Share | N/A | N/A | N/A | 0.00 |
| Shares Out. | 1.5M | 2.8M | 3.0M | 17.5M |
| Valuation | ||||
| P/E Ratio | N/A | N/A | N/A | -3.8 |
| P/FCF | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A |
| Price/Book | N/A | 0.9 | 0.6 | 53.8 |
| Price/Sales | N/A | 12.0 | N/A | N/A |
| FCF Yield | N/A | -72.4% | -151.9% | N/A |
| Market Cap | N/A | 73M | 25M | 205M |
| Avg. Price | N/A | 117.22 | 14.71 | 11.73 |
| Year-End Price | N/A | 25.90 | 8.40 | 11.73 |
Elicio Therapeutics, Inc. passes 1 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 98.4%.
Elicio Therapeutics, Inc. (ELTX) has a 5-year average return on invested capital (ROIC) of -82.4%. This is below average and may indicate limited pricing power.
Elicio Therapeutics, Inc. (ELTX) has a market capitalization of $205M. It is classified as a small-cap stock.
Elicio Therapeutics, Inc. (ELTX) does not currently pay a regular dividend.
Elicio Therapeutics, Inc. (ELTX) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Elicio Therapeutics, Inc. (ELTX) generated $-38 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Elicio Therapeutics, Inc. (ELTX) has a debt-to-equity ratio of 0.00. This indicates a conservatively financed balance sheet.
Elicio Therapeutics, Inc. (ELTX) reported earnings per share (EPS) of $-12.90 in its most recent fiscal year.
Elicio Therapeutics, Inc. (ELTX) has a return on equity (ROE) of -62.0%. A negative ROE may indicate losses or negative equity.
Elicio Therapeutics, Inc. (ELTX) has a 5-year average gross margin of 98.4%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 3 years of financial data for Elicio Therapeutics, Inc. (ELTX), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Elicio Therapeutics, Inc. (ELTX) has a book value per share of $14.55, based on its most recent annual SEC filing.